Royal London Asset Management Ltd. Raises Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Royal London Asset Management Ltd. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,072 shares of the company's stock after purchasing an additional 2,189 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.13% of IDEXX Laboratories worth $52,074,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Chicago Partners Investment Group LLC boosted its position in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after purchasing an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after acquiring an additional 1,453 shares in the last quarter. National Pension Service grew its stake in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after acquiring an additional 12,647 shares during the last quarter. EFG Asset Management Americas Corp. increased its holdings in shares of IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after acquiring an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC raised its position in shares of IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IDXX shares. Barclays dropped their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, November 28th. Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday. They issued an "outperform" rating and a $500.00 target price for the company. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $546.56.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded up $8.20 on Friday, hitting $435.69. The company had a trading volume of 551,918 shares, compared to its average volume of 511,214. The firm has a market cap of $35.68 billion, a P/E ratio of 42.01, a price-to-earnings-growth ratio of 3.95 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a 50-day moving average price of $445.99 and a 200-day moving average price of $475.13. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.53 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.